Welcome, Dr. Qi Liu to Clinical and Translational Science!
Clinical and Translational Science
) is pleased to announce that Qi Liu, PhD, M.Stat., has joined its editorial team as Associate Editor. Dr. Liu currently serves as Associate Director for Innovation & Partnership in the Office of Clinical Pharmacology (OCP) for the US Food and Drug Administration (FDA).
Under her leadership, the OCP has collaborated with internal and external experts to develop a portfolio on machine learning/artificial intelligence, real world evidence, and digital health technologies. In her time at the FDA, she has also contributed more than 200 NDA/sNDA reviews, 20 BLA/sBLA reviews, and numerous IND reviews to support drug development. In addition, Dr. Liu has co-authored close to 60 manuscripts and/or book chapters, presented a variety of topics at FDA Advisory Committee meetings and scientific conferences, contributed to several FDA guidance documents, and helped to develop a Manual of Policies and Procedures. She has co-led the OCP’s Physiological Based Pharmacokinetic Modeling and Simulation Oversight Board, the Biologics Oversight Board, and the Real-Time Oncology Review and Assessment Aid Pilot Programs. Prior to joining the FDA, Dr. Liu held a senior pharmacokineticist position with Merck & Co., Inc. Her educational achievements include a PhD in Pharmaceutics and a Master’s degree in Statistics, both from the University of Florida, as well as a Master’s degree in Pharmaceutics and a Bachelor’s degree in Clinical Pharmacy from West China University of Medical Sciences.
Of course, a new addition to the team often means saying goodbye to a valued member. We wish to thank Michael Pacanowski, PharmD, for his exemplary service to CTS
. He has contributed greatly to the journal’s success in his time as Associate Editor, and his work ethic and insights will be greatly missed. Mike, we’re sad to see you go! We greatly appreciate everything you’ve done for CTS